{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:58:39Z","timestamp":1783403919292,"version":"3.54.6"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Since the advent of immunotherapy in clinical practice, it has profoundly transformed the paradigm of cancer treatment and has been rapidly adopted in clinical settings. Concurrently, the combination of immunotherapy with anti-angiogenic therapy has shown great promise in clinical research. The inevitable joint application brings about a greater number of adverse reactions. These adverse reactions are often perplexing, with the uncertainty of whether they stem from immunotherapy, anti-angiogenic therapy, or both. This is a case report of adverse reactions occurring when immune drugs and anti-vascular drugs are used together. This case is analyzed to provide a warning for adverse reactions in the clinical application of anti-angiogenic therapy combined with immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 52-year-old cervical cancer patient with metastases had abdominal pain and fever post-treatment with bevacizumab, pembrolizumab, and chemotherapy, suggesting intestinal perforation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>After 2 chemotherapy cycles with bevacizumab and pembrolizumab, the patient had fever up to 39\u00b0C and abdominal pain. Exam showed tenderness, rigidity, and weak bowel sounds. Blood tests revealed leukocytosis and neutrophilia. Imaging indicated pneumoperitoneum and possible intestinal obstruction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Emergency laparotomy revealed a small intestine perforation with strictures, leading to resection and ileostomy due to edema.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The postoperative recovery was good. We consider intestinal perforation caused by bevacizumab. Therefore, the patient was subsequently discontinued from bevacizumab and continued to receive paclitaxel, cisplatin and pembrolizumab. At present, the patient has finished chemotherapy and is receiving pembrolizumab maintenance therapy with no significant gastrointestinal adverse reactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Anti-angiogenic drugs and immunotherapy drugs each have their own side effects, and the occurrence of adverse reactions becomes more complex when used in combination. In the clinical process of combined medication, more attention should be paid to adverse reactions, early identification of severe adverse reactions, and active management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040473","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:01:00Z","timestamp":1744664460000},"page":"e40473","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Intestinal perforation in recurrent cervical cancer following bevacizumab and pembrolizumab therapy: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Yuanchun","family":"Fan","sequence":"first","affiliation":[{"name":"The Gynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Liu","sequence":"additional","affiliation":[{"name":"The Gynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangjing","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Gynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Fu","sequence":"additional","affiliation":[{"name":"The Gynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Yang","sequence":"additional","affiliation":[{"name":"The Gynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Wang","sequence":"additional","affiliation":[{"name":"The Gynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-9334","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Gynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250414","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting.","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol"},{"key":"R2-20250414","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors.","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"R3-20250414","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma.","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R4-20250414","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"R5-20250414","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"R6-20250414","article-title":"Avastin: Prescribing information.","year":"2021"},{"key":"R7-20250414","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook.","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R8-20250414","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer.","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20250414","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/IGC.0000000000001000","article-title":"Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer.","volume":"27","author":"Rosen","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R10-20250414","first-page":"e14093","article-title":"Intestinal perforation: a rare complication of treatment with bevacizumab.","volume":"13","author":"Adhikari","year":"2021","journal-title":"Cureus"},{"key":"R11-20250414","doi-asserted-by":"crossref","first-page":"e1952","DOI":"10.1002\/cnr2.1952","article-title":"Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer.","volume":"7","author":"Fang","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"R12-20250414","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ags3.12312","article-title":"Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab.","volume":"4","author":"Yoshimoto","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"key":"R13-20250414","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13256-018-1619-x","article-title":"Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.","volume":"12","author":"Fujii","year":"2018","journal-title":"J Med Case Rep"},{"key":"R14-20250414","first-page":"437","article-title":"Bevacizumab-induced bowel perforation.","volume":"111","author":"Sliesoraitis","year":"2011","journal-title":"J Am Osteopath Assoc"},{"key":"R15-20250414","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","article-title":"Practical management of bevacizumab-related toxicities in glioblastoma.","volume":"20","author":"Brandes","year":"2015","journal-title":"Oncologist"},{"key":"R16-20250414","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse Events of Concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review.","volume":"10","author":"Gao","year":"2019","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"R17-20250414","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.3393\/ac.2020.00213.0030","article-title":"Colonic perforation after treatment with nivolumab in esophageal cancer: a case report.","volume":"37","author":"Cho","year":"2021","journal-title":"Ann Coloproctol"},{"issue":"3_suppl","key":"R18-20250414","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2021.39.3_suppl.6","article-title":"KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.","volume":"39","author":"Shiu","year":"2021","journal-title":"J Clin Oncol"},{"key":"R19-20250414","first-page":"S2239253X15024287","article-title":"Solitary metastasis from melanoma causing bowel perforation.","volume":"86","author":"Guercio","year":"2015","journal-title":"Ann Ital Chir"},{"key":"R20-20250414","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.3802\/jgo.2019.30.e56","article-title":"Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.","volume":"30","author":"Normann","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"R21-20250414","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:01:03Z","timestamp":1744664463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":21,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040473","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}